The mystery of the mystery of common genetic diseases

Biology and Philosophy

Volumn 25, Issue 2, 2010, Pages 183-201

  Valles, Sean A ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Cystic fibrosis; Founder effect; Genetic disease; Heterozygote advantage; Random genetic drift; Reproductive compensation; Tay Sachs disease

Indexed keywords

DISEASE; FOUNDER EFFECT; GENETIC DRIFT; HETEROZYGOSITY; MUTATION; PHENOTYPE;

EID: 78650715182     PISSN: 01693867     EISSN: 15728404     Source Type: Journal    
DOI: 10.1007/s10539-009-9184-8     Document Type: Article

References (47)

1. Bowersox J (1998) Cystic fibrosis protects against typhoid fever (news release). National Institutes of Health, Bethesda
2. Bowman J (1964) Comments on abnormal erythrocytes and malaria. Am J Trop Med Hyg 13(suppl): 159-161
3. Bowman JE, Carson PE, Frischer H, Powell RD, Colwell EJ, Legters LJ et al (1971) Hemoglobin and red cell enzyme variation in some populations of the Republic of Vietnam with comments on the malria hypothesis. Am J Phys Anthropol 34(3):313-324
4. Bromberger S (1966) Why-questions. In: Colodny RG (ed) Mind and cosmos: essays in contemporary science and philosophy. University of Pittsburgh Press, Pittsburgh, pp 86-111
5. Calafell F, Cutting G, Dodge J, Des Georges M, Dork T, Durie P et al (2004) The molecular genetic epidemiology of cystic fibrosis: report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS Genoa, Italy, 19 June 2002. World Health OrganizationChronic Diseases and Health Promotion Human Genetics Programme, Geneva
6. Charrow J (2004) Ashkenazi jewish genetic disorders. Familial Cancer 3(3-4):201-206
7. Chase GA, McKusick VA (1972) Controversy in human genetics: founder effect in tay-sachs disease. Am J Hum Genet 24(3):339-340
8. Diamond JM (1988) Diamond replies. Nature 331(6158):666
9. Diamond J (1991) Curse and blessing of the Ghetto. Discover 12:60-65
10. Diamond J (1994) Human genetics. Jewish lysosomes. Nature 368(6469):291-292
11. Flint J, Harding RM, Clegg JB, Boyce AJ (1993) Why are some genetic diseases common? Hum Genet 91(2):91-117
12. Frisch A, Colombo R, Michaelovsky E, Karpati M, Goldman B, Peleg L (2004) Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: genetic drift as a Robust and Parsimonious hypothesis. Hum Genet 114(4):366-376
13. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ (1994) Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266(5182):107-109
14. Gallego Romero I, Ober C (2008) CFTR mutations and reproductive outcomes in a population isolate. Hum Genet 122(6):583-588
15. Gould SJ, Lewontin RC (1979) The Spandrels of San Marco and the Panglossian Paradigm: a critique of the adaptationist programme. Proc R Soc Lond Ser B Biol Sci 205(1161):581-598
16. Harris EE, Malyango AA (2005) Evolutionary explanations in medical and health profession courses: are you answering your students' "Why" questions? BMC Med Educ 5(1):16
17. Hastings IM (2000) Models of human genetic disease: how biased are the standard formulae? Genet Res 75(1):107-114
18. Hogenauer C, Santa Ana CA, Porter JL, Millard M, Gelfand A, Rosenblatt RL et al (2000) Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion. Am J Hum Genet 67(6):1422-1427
19. Jorde LB, Lathrop GM (1988) A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers. Am J Hum Genet 42(6):808-815
20. Knudson AG, Jr, Wayne L, Hallett WY (1967) On the selective advantage of cystic fibrosis heterozygotes. Am J Hum Genet 19(3 Pt 2):388-392
21. Koeslag JH, Schach SR, Melzer CW (1984) Tay-Sachs disease and the persistence of lethal autosomal recessive genes in human populations. S Afr Med J 66(3):87-89
22. Lewis LG, Cohen MB (1995) A selective advantage for cystic fibrosis carriers. J Pediatr Gastroenterol Nutr 21(1):117-118
23. Lewontin RC (1953) The effect of compensation on populations subject to natural selection. Am Nat 87(837):375-381
24. Livingstone FB (1971) Malaria and human polymorphisms. Annu Rev Genet 5:33-64
25. Lloyd EA (1994) The structure and confirmation of evolutionary theory. Princeton University Press, Princeton
26. Meals RA (1971) Paradoxical frequencies of recessive disorders in Ashkenazic Jews. J Chronic Dis 23:547-558
27. Modiano G, Ciminelli BM, Pignatti PF (2007) Cystic fibrosis and lactase persistence: a possible correlation. Eur J Hum Genet 15(3):255-259
28. Myrianthopoulos NC, Aaronson SM (1971). Population dynamics of Tay Sachs Disease. II. What confers the selective advantage upon the jewish heterozygote? Paper presented at the symposium on sphingolipidoses and allied disorders, New York
29. Myrianthopoulos NC, Aronson SM (1966) Population dynamics of Tay-Sachs Disease. I. Reproductive fitness and selection. Am J Hum Genet 18(4):313-327
30. O'Brien SJ (1991) Ghetto legacy. Curr Biol 1(4):209-211
31. Peach SL, Borriello SP, Gaya H, Barclay FE, Welch AR (1986) Asymptomatic carriage of clostridium difficile in patients with cystic fibrosis. J Clin Pathol 39(9):1013-1018
32. Pier GB, Grout M, Zaidi T, Meluleni G, Mueschenborn SS, Banting G et al (1998) Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 393(6680):79-82
33. Poolman EM, Galvani AP (2007) Evaluating candidate agents of selective pressure for cystic fibrosis. J R Soc Interface 4(12):91-98
34. Qin J, Calabrese P, Tiemann-Boege I, Shinde DN, Yoon S-R, Gelfand D et al (2007) The molecular anatomy of spontaneous germline mutations in human testes. PLoS Biol 5(9):e224
35. Risch N, Tang H, Katzenstein H, Ekstein J (2003) Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am J Hum Genet 72(4):812-822
36. Rodman DM, Zamudio S (1991) The cystic fibrosis heterozygote-advantage in surviving cholera? Med Hypotheses 36(3):253-258
37. Rotter JI, Diamond JM (1987) What maintains the frequencies of human genetic diseases? Nature 329(6137):289-290
38. Schaffner KF (1993) Discovery and explanation in biology and medicine. University of Chicago Press, Chicago
39. Spyropoulos B, Moens PB, Davidson J, Lowden JA (1981) Heterozygote advantage in Tay Sachs carriers? Am J Hum Genet 33(3):375-380
40. Stiehm ER (2006) Disease versus disease: how one disease may ameliorate another. Pediatrics 117(1):184-191
41. Temple D (1988) The contrast theory of why-questions. Philos Sci 55(1):141-151
42. van de Vosse E, Ali S, de Visser AW, Surjadi C, Widjaja S, Vollaard AM et al (2005) Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR). Hum Genet 118(1):138-140
43. van Fraassen BC (1990) The scientific image. Oxford University Press, New York
44. Walsh DM, Lewens T, Ariew A (2002) The trials of life: natural selection and random drift. Philos Sci 69(3):452-473
45. Wright SW, Morton NE (1968) Genetic studies on cystic fibrosis in Hawaii. Am J Hum Genet 20(2): 157-169
46. Zlotogora J (1994) High frequencies of human genetic diseases: founder effect with genetic drift or selection? Am J Med Genet 49(1):10-13
47. Zlotogora J (1998) Selection for carriers of recessive diseases: a common phenomenon? Am J Med Genet 80(3):266-268